Child vaccination policies in Europe: A report from the summits of independent European vaccination experts

Lancet Infectious Diseases

Volumn 3, Issue 2, 2003, Pages 103-108

  Schmitt, Heinz J ^a   Booy, Robert ^b   Weil Olivier, Catherine ^c   Van Damme, Pierre ^d   Cohen, Robert ^e   Peltola, Heikki ^f  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c HÔPITAL LOUIS MOURIER   (France)

^d Ctr for the Eval of Vaccination   (Belgium)

^e CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD CARE; EDUCATION; EUROPE; EXPERT SYSTEM; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INFECTION CONTROL; MEASLES; PRIORITY JOURNAL; PUBLIC HEALTH; REFUGEE; REVIEW; SAFETY; VACCINATION;

EID: 0037310478     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00519-X     Document Type: Review

References (38)

1. Salmaso S, Gabutti G, Rota MC, et al, Pattern of susceptibility to measles in Italy. Bull World Health Organ 2000; 78: 950-55.
2. Payne D. Ireland's measles outbreak kills two. BMJ 2000;321:197.
3. Oppermann H. The status of vaccine preventable diseases in Germany. Gesundheitswesen 2001; 63: 102-06.
4. Rotily M, Guagliardo V, Fontaine D, et al. Evaluation de la couverture vaccinale rougeoleoreillons-rubéole chez les enfants de trois ans dans douze départements françois: evolution temporelle et facteurs associés. Rev Epidemiol Sante Publique 2001; 49: 331-41.
5. Bonmarin I, Levy-Bruhl D. Measles in France: the epidemiological impact of suboptimal immunisation coverage. Eurosurveiltance 2002; 7: 55-60.
6. Robert Koch-Institut. Übersicht zum Masernausbruch in Coburg. Epidemiol Bull 2002; 19: 155.
7. Ciofi degli Atti M, Salmaso S, Measles increase in Italy. http://www.eurosurv.org/2002/020404.html (accessed Dec 17, 2002).
8. Ehrengut W. Adverse effects of pertussis vaccination in west Germany (1970-1978). Dtsch Med Wochenschr 1985; 110: 974-75.
9. Vallely P, One jab good, three jabs bad. The Independent 2001 Aug 21; http://www.independent.co.uk/story.jsp?story=89761 (accessed Jan 7 2003).
10. Wakefield AJ, Murch SH, Anthony A, et al. Ileallymphoid-nodular hyperplasia, non-specific colitis,and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
11. Wakefield Al, Puleston JM, Montgomery SM, Anthony A, O'Leary JJ, Murch SH. The concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002; 16: 663-74.
12. Mills H. Measles-mumps-rubella: the story so far - a comprehensive review of the MMR vaccination/autism controversy. Private Eye Special Report (London), May 2002: 1-31.
13. Evans G. Vaccine injury compensation programs worldwide. Vaccine 1999; 17 (suppl 3): S25-35.
14. Glismann S, Ronne T, Schmidt JE. The EUVACNET survey: national measles surveillance systems in the EU, Switzerland, Norway and Iceland. Eurosurveillance 2001; 6:105-10.
15. Fleischmann L Impfen? Wer will das eigentlich? Ärzteblatt Rheinland-Pfalz (Köln), 2002; 5: 4.
16. Lauberau B, Hermann M, Weil J, Schmitt H, von Kries R. Durchimpfungsraten bei Kindern in Deutschland 1999. Monatsschr Kinderheilkunde 2001; 149: 367-72.
17. Krause G. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2001. Berlin: Robert Koch-Institut, 2002.
18. Anon. RKI- Ratgeber Infektionskrankheiten: Masern. Epidemiol Bull 2002; 6: 41.
19. Kirschner W, Kirschner R, Koch L Impfaufklärung verbessert Durchimpfungsraten. Kinderärztliche Praxis 1997; 68: 7-12.
20. Elliman DA, Bedford HE. MMR vaccine-worries are not justified. Arch Dis Child 2001; 85: 271-74.
21. Patja A, Davidkin I, Kurki T, Kallio MJT, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis/2000;19 1227-34.
22. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999;17 (suppl 3): S41-46.
23. Durand de Bousingen D. Drug firm compensates patients for suspected hepatitis B vaccine failure. Lancet 2001; 357: 1598.
24. Touze E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 2002; 21: 180-86.
25. Sievers EJ, Heyneman CA. Relationship between vaccinations and multiple sclerosis. Ann Pharmacother 2002; 36: 160-62.
26. American Academy of Pediatrics. Evidence doesn't support autism/vaccine link: new report adds to mounting studies 2001. http://www.aap.org/advocacy/washing/23apr01.htm (accessed Dec 17, 2002).
27. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19: 3632-35.
28. Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics 2001; 107: E84.
29. Stratton K, Gable A, Shetty P, McCormick M, on behalf of the Immunization Review Committee. Measles-mumps-rubella vaccine and autism. Washington DC: Institute of Medicine, National Academy Press, 2001.
30. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356-61.
31. Schmitt HJ, Just M, Neiss A. Withdrawal of a mumps vaccine: reasons and impacts. Eur J Pediatr 1993;152:387-88.
32. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48: 577-81.
33. Linhares AC, Gabbay YB, Mascarenhas JDP, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human reassortant rotavirus vaccine in Belém, Brasil. Bull World Health Organ 1996; 74: 491-500.
34. Weijer C. The future of research into rotavirus vaccine. BMJ 2000; 321: 525-26.
35. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
36. Eskola J, Kipi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-09.
37. Desenclos J-C. Vaccine preventable diseases: a regional surveillance can help improve data comparability between countries. Eurosurveillance 2001; 6: 93-94.
38. Anon. Hinweise auf Ausbrühe von besonderer Bedeutung. Epidemiol Bull 2002; 11: 96.